LEADER 01817nam 2200493 450 001 9910807145303321 005 20230803205920.0 010 $a1-78319-696-3 035 $a(CKB)3710000000272725 035 $a(EBL)1829394 035 $a(MiAaPQ)EBC5511508 035 $a(MiAaPQ)EBC1829394 035 $a(Au-PeEL)EBL1829394 035 $a(OCoLC)894791220 035 $a(EXLCZ)993710000000272725 100 $a20220519d2014 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aThis is how we die /$fChristopher Brett Bailey 210 1$aLondon, England :$cOberon Books,$d[2014] 210 4$dİ2014 215 $a1 online resource (58 p.) 225 1 $aOberon modern plays 300 $aDescription based upon print version of record. 311 $a1-78319-197-X 327 $aCover; Title Page; About the Author; Critical Acclaim for This is How We Die; Copyright; Contents; Chapter 1 330 $a a motor-mouthed collage of spoken word and storytelling. tales of paranoia, young love and ultra-violence... from the desk of christopher brett bailey comes a spiraling odyssey of pitch-black humour and nightmarish prose.
THIS IS HOW WE DIE is a prime slice of surrealist trash, an Americana death trip and a dizzying exorcism for a world convinced it is dying... 410 0$aOberon modern plays. 606 $aEnglish drama 606 $aYouth and death 615 0$aEnglish drama. 615 0$aYouth and death. 676 $a822.92 700 $aBailey$b Christopher Brett$01619613 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910807145303321 996 $aThis is how we die$93951970 997 $aUNINA LEADER 04630nam 2200697 a 450 001 9910953430403321 005 20251017110221.0 010 $a0-309-21493-9 010 $a1-283-25354-2 010 $a9786613253545 010 $a0-309-21491-2 035 $a(CKB)2550000000051836 035 $a(EBL)3378855 035 $a(SSID)ssj0000533788 035 $a(PQKBManifestationID)11319018 035 $a(PQKBTitleCode)TC0000533788 035 $a(PQKBWorkID)10504138 035 $a(PQKB)10851009 035 $a(MiAaPQ)EBC3378855 035 $a(Au-PeEL)EBL3378855 035 $a(CaPaEBR)ebr10495455 035 $a(CaONFJC)MIL325354 035 $a(OCoLC)923284117 035 $a(DNLM)1571930 035 $a(EXLCZ)992550000000051836 100 $a20111003d2011 uy 0 101 0 $aeng 135 $auruz#---auuu| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aAdvancing regulatory science for medical countermeasure development $eworkshop summary /$fTheresa Wizemann, Bruce M. Altevogt, and Anne B. Claiborne, rapporteurs 205 $a1st ed. 210 $aWashington, D.C. $cNational Academies Press$d2011 215 $a1 online resource (150 pages) 300 $aDescription based upon print version of record. 311 08$a0-309-21490-4 320 $aIncludes bibliographical references. 327 $a""Front Matter""; ""Reviewers""; ""Contents""; ""Tables, Figures, and Boxes""; ""Acronyms""; ""1 Introduction""; ""2 MCM Enterprise and Stakeholder Perspectives""; ""3 Cutting-Edge Efforts to Advance MCM Regulatory Science""; ""4 MCM Regulatory Science Needs for At-Risk Populations""; ""5 Crosscutting Themes and Future Directions""; ""6 Closing Remarks""; ""References""; ""Appendix A: Workshop Agenda""; ""Appendix B: Participant Biographies"" 330 $aWhether or not the United States has safe and effective medical countermeasures--such as vaccines, drugs, and diagnostic tools--available for use during a disaster can mean the difference between life and death for many Americans. The Food and Drug Administration (FDA) and the scientific community at large could benefit from improved scientific tools and analytic techniques to undertake the complex scientific evaluation and decision making needed to make essential medical countermeasures available. At the request of FDA, the Institute of Medicine (IOM) held a workshop to examine methods to improve the development, evaluation, approval, and regulation of medical countermeasures. During public health emergencies such as influenza or chemical, biological, radiological/nuclear (CBRN) attacks, safe and effective vaccines, treatments, and other medical countermeasures are essential to protecting national security and the well being of the public. Advancing regulatory science for medical countermeasure development examines current medical countermeasures, and investigates the future of research and development in this area. Convened on March 29-30, 2011, this workshop identified regulatory science tools and methods that are available or under development, as well as major gaps in currently available regulatory science tools. Advancing regulatory science for medical countermeasure development is a valuable resource for federal agencies including the Food and Drug Administration (FDA), the Department of Health and Human Services (HHS), the Department of Defense (DoD), as well as health professionals, and public and private health organizations"--Publisher's description. 606 $aEmergency management$zUnited States$xEvaluation$vCongresses 606 $aDisaster medicine$zUnited States$xEvaluation$vCongresses 606 $aWeapons of mass destruction$xHealth aspects$vCongresses 606 $aChemical agents (Munitions)$vCongresses 615 0$aEmergency management$xEvaluation 615 0$aDisaster medicine$xEvaluation 615 0$aWeapons of mass destruction$xHealth aspects 615 0$aChemical agents (Munitions) 676 $a616.0250973 701 $aWizemann$b Theresa M$0890630 701 $aAltevogt$b Bruce M$01791694 701 $aClaiborne$b Anne B$01805914 712 02$aInstitute of Medicine (U.S.).$bForum on Drug Discovery, Development, and Translation. 712 02$aInstitute of Medicine (U.S.).$bForum on Medical and Public Health Preparedness for Catastrophic Events. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910953430403321 996 $aAdvancing regulatory science for medical countermeasure development$94446304 997 $aUNINA